3rd Edition of International Obesity and Metabolism Conference 2027

Obesity remains a major global health challenge; however, current pharmacotherapies are often limited by safety concerns and significant weight regain following treatment cessation. LXP103 is a novel investigational compound evaluated for its potential to induce safe and durable weight reduction while maintaining an acceptable systemic profile. In this study, diet-induced obese (DIO) rats received subcutaneous injections of LXP103 once weekly for four consecutive weeks, followed by a two-week drug-free observation period to assess weight rebound. LXP103 treatment significantly attenuated overall body-weight gain compared to the control group. Crucially, this suppression of weight gain was maintained during the post-treatment period with no significant rebound trend, suggesting a potential benefit in mitigating weight regain after treatment withdrawal. In parallel, LXP103 markedly reduced abdominal fat-pad thickness and improved abdominal morphology at the treated site, demonstrating robust anti-obesity activity regarding both body weight and local adiposity. No treatment-related systemic toxicity or overt inflammatory responses were detected, as major organ weights and serum biochemical markers—including AST, ALT, BUN, and creatinine—remained within physiological ranges throughout the study, indicating a favourable safety profile. Furthermore, serum lipid analysis revealed stable total cholesterol levels and a significant reduction in triglycerides following LXP103 administration, consistent with an overall metabolic benefit. Collectively, these findings demonstrate that LXP103 exerts a strong weight-reducing effect with sustained efficacy after treatment cessation, accompanied by improvements in adipose morphology and circulating triglyceride levels. Therefore, LXP103 represents a promising therapeutic candidate for safe and durable weight management in the context of obesity and related metabolic disorders.